Substance use histories in patients seeking treatment for controlled-release oxycodone dependence

被引:44
|
作者
Potter, JS
Hennessy, G
Borrow, JA
Greenfield, SF
Weiss, RD
机构
[1] McLean Hosp, Belmont, MA 02478 USA
[2] Harvard Univ, Sch Med, Belmont, MA 02478 USA
关键词
prescription opiate abuse; oxycodone; pain patients;
D O I
10.1016/j.drugalcdep.2004.05.001
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
The characteristics of patients currently abusing control led-release (CR) oxycodone admitted for inpatient detoxification were ascertained from medical record review of 48 inpatients with CR oxycodone dependence. Patients were categorized according to the manner in which they initially received the drug: illicitly or by prescription for legitimate medical use. Fifteen of the 48 patients (31%) initially obtained a CR oxycodone prescription legitimately for a medical condition. While none of these 15 patients had a history of prior opioid misuse, they were more likely than illicit CR oxycodone users to report prior detoxifications (P < 0.03) as well as a lower mean age of first alcohol use (legitimate = 11.7 versus illicit = 14.7, P < 0.05) and first illicit drug use (legitimate = 12.8 versus illicit = 15.8, P < 0.05). These findings suggest that a history of substance abuse is common among patients abusing CR oxycodone, including individuals for whom CR oxycodone was initially legitimately prescribed for pain. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:213 / 215
页数:3
相关论文
共 50 条
  • [21] Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients
    Fujiwara, Yutaka
    Toyoda, Masanori
    Chayahara, Naoko
    Kiyota, Naomi
    Shimada, Takanobu
    Imamura, Yoshinori
    Mukohara, Toru
    Minami, Hironobu
    PLOS ONE, 2014, 9 (08):
  • [22] Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain
    Kaplan, R
    Parris, WCV
    Citron, ML
    Zhukovsky, D
    Reder, RF
    Buckley, BJ
    Kaiko, RF
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) : 3230 - 3237
  • [23] The use of controlled-release oxycodone for the treatment of chronic cancer pain: A randomized, double-blind study
    Parris, WCV
    Johnson, BW
    Croghan, MK
    Moore, MR
    Khojasteh, A
    Reder, RF
    Kaiko, RF
    Buckley, BJ
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1998, 16 (04) : 205 - 211
  • [24] Controlled-release oxycodone for the management of pediatric postoperative pain
    Czarnecki, ML
    Jandrisevits, MD
    Theiler, SC
    Huth, MM
    Weisman, SJ
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2004, 27 (04) : 379 - 386
  • [25] Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone
    Kaiko, RF
    Benziger, DP
    Fitzmartin, RD
    Burke, BE
    Reder, RF
    Goldenheim, PD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (01) : 52 - 61
  • [26] Controlled-release (CR) oxycodone for the treatment of Bortezomib-induced neuropathic pain in patients with multiple myeloma
    Cartoni, C.
    Brunetti, G.
    D'Elia, G. M.
    Niscola, P.
    Favale, E.
    Alfieri, P. L.
    Dizdari, A.
    Morano, S. G.
    Annechini, G.
    Foa, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 195 - 195
  • [27] Clinical pharmacokinetics of controlled-release oxycodone in renal impairment
    Kaiko, R
    Benziger, D
    Cheng, C
    Hou, Y
    Grandy, R
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PI3 - PI3
  • [28] Controlled-release oxycodone and morphine in cancer related pain
    Heiskanen, T
    Kalso, E
    PAIN, 1997, 73 (01) : 37 - 45
  • [29] Analgesic efficacy of controlled-release oxycodone in postoperative pain
    Sunshine, A
    Olson, NZ
    Colon, A
    Rivera, J
    Kaiko, RF
    Fitzmartin, RD
    Reder, RF
    Goldenheim, PD
    JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (07): : 595 - 603
  • [30] Characterization and validation of a pharmacokinetic model for controlled-release oxycodone
    Mandema, JW
    Kaiko, RF
    Oshlack, B
    Reder, RF
    Stanski, DR
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (06) : 747 - 756